Decreased miR-340 Expression in Bone Marrow Is Associated with Liver Metastasis of Colorectal Cancer

Studies have shown the prognostic significance of disseminated tumor cells (DTC) in bone marrow of patients with colorectal cancer. However, the molecular characteristics of DTCs, including their miRNA expression profiles, remain mostly unknown. In this study, we analyzed the miRNA expression of DTCs in bone marrow. EpCAM+ bone marrow cells were collected using immunomagnetic beads after exclusion of CD14+ and CD45+ cells, then subjected to miRNA microarray analysis. Cluster analysis (7 colorectal cancer patients with liver metastasis and 12 colorectal cancer patients without liver metastasis) indicated that miR-340 and miR-542-3p expressions were significantly decreased in EpCAM+ bone marrow cells of patients with liver metastasis (P = 0.019 and 0.037, respectively). We demonstrated that pre-miR-340 administration inhibited growth of colon cancer cells and suppressed c-Met expression in vitro. In clinical samples of colorectal cancer, miR-340 was expressed at significantly lower levels in tumor tissues compared with normal mucosa. Survival analysis in 136 patients with colorectal cancer indicated that low miR-340 expression was correlated with shorter 5-year disease-free survival (P = 0.023) and poor 5-year overall survival (P = 0.046). It was of note that the colorectal cancer group with low miR-340 and high c-Met expression had the worst prognosis. We further demonstrated that systemic pre-miR-340 administration suppressed growth of pre-established HCT116 tumors in animal therapeutic models. These findings indicate that miR-340 may be useful as a novel prognostic factor and as a therapeutic tool against colorectal cancer. Our data suggest that miR-340 in bone marrow may play an important role in regulating the metastasis cascade of colorectal cancer. Mol Cancer Ther; 13(4); 976–85. ©2014 AACR.

[1]  V. Spiegelman,et al.  MicroRNA-340-mediated degradation of microphthalmia-associated transcription factor mRNA is inhibited by the coding region determinant-binding protein. , 2014, The Journal of Biological Chemistry.

[2]  Jan Lubinski,et al.  MiRNA‐362‐3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer , 2013, International journal of cancer.

[3]  P. Tan,et al.  Identification of Circulating MicroRNA Signatures for Breast Cancer Detection , 2013, Clinical Cancer Research.

[4]  Y. Doki,et al.  Fabrication and Intracellular Delivery of Doxorubicin/Carbonate Apatite Nanocomposites: Effect on Growth Retardation of Established Colon Tumor , 2013, PloS one.

[5]  K. Gopinath,et al.  Oncogenic MicroRNA-155 Down-regulates Tumor Suppressor CDC73 and Promotes Oral Squamous Cell Carcinoma Cell Proliferation , 2012, The Journal of Biological Chemistry.

[6]  C. Marsden,et al.  Disseminated Breast Cancer Cells Acquire a Highly Malignant and Aggressive Metastatic Phenotype during Metastatic Latency in the Bone , 2012, PloS one.

[7]  Yu Hu,et al.  miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect. , 2012, Oncology reports.

[8]  K. Mimori,et al.  Clinical significance of miR-144-ZFX axis in disseminated tumour cells in bone marrow in gastric cancer cases , 2012, British Journal of Cancer.

[9]  E. Morii,et al.  MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression , 2012, Oncogene.

[10]  Xiao-nan Wang,et al.  miR‐340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c‐Met , 2011, Cancer.

[11]  B. Trink,et al.  Phospho-ΔNp63α is a key regulator of the cisplatin-induced microRNAome in cancer cells , 2011, Cell Death and Differentiation.

[12]  Ru-Fang Yeh,et al.  TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer , 2011, Science Signaling.

[13]  J. Nesland,et al.  Disseminated tumour cells as a prognostic biomarker in colorectal cancer , 2011, British Journal of Cancer.

[14]  K. Kelnar,et al.  The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. , 2011, Nature medicine.

[15]  L. Vermeulen,et al.  Cancer stem cell niche: the place to be. , 2011, Cancer research.

[16]  T. Akaike,et al.  Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[17]  Suman Lee,et al.  Induction of growth arrest by miR‐542‐3p that targets survivin , 2010, FEBS letters.

[18]  Klaus Pantel,et al.  Circulating tumour cells in cancer patients: challenges and perspectives. , 2010, Trends in molecular medicine.

[19]  K. Kelnar,et al.  Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. , 2010, Cancer research.

[20]  L. Terracciano,et al.  Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer , 2010, British Journal of Cancer.

[21]  V. Spiegelman,et al.  MicroRNA-340-mediated Degradation of Microphthalmia-associated Transcription Factor mRNA Is Inhibited by the Coding Region Determinant-binding Protein* , 2010, The Journal of Biological Chemistry.

[22]  M. Ellis,et al.  Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. , 2010, The Lancet. Oncology.

[23]  Shuai Jiang,et al.  MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. , 2010, Cancer research.

[24]  Ming Yao,et al.  Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA , 2010, Nature Cell Biology.

[25]  E. Barillot,et al.  miR-181a and miR-630 regulate cisplatin-induced cancer cell death. , 2010, Cancer research.

[26]  Hansjuerg Alder,et al.  miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. , 2009, Cancer cell.

[27]  J. Köllermann,et al.  Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  F. Barany,et al.  c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. , 2008, Cancer letters.

[29]  K. Mimori,et al.  Hematogenous Metastasis in Gastric Cancer Requires Isolated Tumor Cells and Expression of Vascular Endothelial Growth Factor Receptor-1 , 2008, Clinical Cancer Research.

[30]  S. K. Zaidi,et al.  MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. , 2008, Cancer research.

[31]  F. Slack,et al.  The let-7 microRNA reduces tumor growth in mouse models of lung cancer , 2008, Cell cycle.

[32]  Ladan Fazli,et al.  Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development , 2007, Proceedings of the National Academy of Sciences.

[33]  Giovanni Vanni Frajese,et al.  miR-221 and miR-222 Expression Affects the Proliferation Potential of Human Prostate Carcinoma Cell Lines by Targeting p27Kip1* , 2007, Journal of Biological Chemistry.

[34]  Jaw-Yuan Wang,et al.  Multiple Molecular Markers as Predictors of Colorectal Cancer in Patients with Normal Perioperative Serum Carcinoembryonic Antigen Levels , 2007, Clinical Cancer Research.

[35]  R. Ach,et al.  Direct and sensitive miRNA profiling from low-input total RNA. , 2006, RNA.

[36]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[37]  A. Giuliano,et al.  Most Early Disseminated Cancer Cells Detected in Bone Marrow of Breast Cancer Patients Have a Putative Breast Cancer Stem Cell Phenotype , 2006, Clinical Cancer Research.

[38]  A. Maruyama,et al.  pH-sensing nano-crystals of carbonate apatite: effects on intracellular delivery and release of DNA for efficient expression into mammalian cells. , 2006, Gene.

[39]  M Vasei,et al.  Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers , 2006, British Journal of Cancer.

[40]  T. Fehm,et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.

[41]  T. Gruenberger.  Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases , 2005, European Surgery.

[42]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[43]  Ruud H. Brakenhoff,et al.  Dissecting the metastatic cascade , 2004, Nature Reviews Cancer.

[44]  M. Monden,et al.  JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1. , 2003, Gastroenterology.

[45]  H. Kato,et al.  Prognostic value of cytokeratin-positive cells in the bone marrow and lymph nodes of patients with resected nonsmall cell lung cancer: a multicenter prospective study. , 2003, The Annals of thoracic surgery.

[46]  M. Monden,et al.  Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  G Kvalheim,et al.  Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  M. Salgaller.  American Association for Cancer Research , 2000, Expert opinion on investigational drugs.

[49]  M. Banerjee,et al.  Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  K. Pantel,et al.  Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases , 1996, The Lancet.

[51]  Yusuke Yamamoto,et al.  Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[52]  René Bernards,et al.  A progression puzzle. , 2002, Nature.